2133 Prospective Evaluation of Health-Related Quality of Life and Neurocognitive Status in Patients With Glioblastoma Multiforme Treated on a Phase II Trial of Hypofractionated Radiation Therapy With Temozolomide K. Reddy, L.E. Gaspar, B.D. Kavanagh, A. Waziri, and C. Chen; University of Colorado Denver, Aurora, CO Purpose/Objective(s): To report the health-related quality of life (HRQOL) and cognitive status in patients with glioblastoma multiforme (GBM) treated on a phase II trial of hypofractionated intensity-modulated radiation therapy (hypo-IMRT) with temozolomide (TMZ). Materials/Methods: Patients with newly diagnosed GBM s/p surgery received postoperative hypo-IMRT to 60 Gy in 10 fractions with concurrent (75 mg/m 2 /d for 30 days) and adjuvant (150-200 mg/m 2 /d for 5 days every 28 days) TMZ. HRQOL was a secondary endpoint, assessed using the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire core-30 and the EORTC brain cancer module, performed at baseline, RT completion, 1 mo post-RT, and every 3 mos thereafter. Cognitive function was determined by Mini Mental Status Examination (MMSE), performed with HRQOL assess- ments. Changes from baseline were calculated for global health status/ quality of life (GH), physical functioning (PF), role functioning (RF), emotional functioning (EF), cognitive functioning (CF), social func- tioning (SF), fatigue, nausea/vomiting (NV), insomnia, appetite loss, future uncertainty, vision, motor dysfunction, communication deficit, headache, seizure and drowsiness. At each time point, a  10 point change in the mean value of any HRQOL scale compared to the mean baseline score was defined as significant. A change of > 3 points in MMSE was also deemed significant. Results: Twenty-four patients were treated on the trial, with a median OS of 16.6 mos (range, 4.1 - 35.9 mos). Compliance with HRQOL assess- ments at baseline, RT completion, and 1, 3, 6, 9, and 12 mos post-RT was 100%, 96%, 92%, 79%, 70%, 68% and 53%, respectively. Up to 12 mos post-RT, no significant changes were seen in GH, PF, RF, EF, fatigue, NV, vision, headache, or seizure. Significant improvement was seen in insomnia, future uncertainty, motor dysfunction, and drowsiness. Signifi- cant worsening was observed in CF (-12.4 at 9 mos; no longer significant at 12 mos), SF (-10.7 at 9 mos; no longer significant at 12 mos), appetite loss (+12.1 at RT completion; no longer significant at 3 mos post-RT), and communication deficit (+16.7 at 9 mos). Five patients had significant worsening in MMSE, with a median decline of 7 points (range, 4-13). For these patients, the mean interval between MMSE decline and radiographic evidence of recurrence was 1.2 mos (range, 0 - 3.8 mos). Conclusions: Sixty Gy hypo-IMRT delivered in 6-Gy fractions with TMZ does not appear to negatively impact overall HRQOL, with improvements seen in specific domains. All HRQOL domains with significant decline post-RT had subsequent improvement, except for communication deficit. The timing of neurocognitive decline is closely tied to disease progression. Author Disclosure: K. Reddy: None. L.E. Gaspar: None. B.D. Kavanagh: None. A. Waziri: None. C. Chen: None. 2134 Dynamic Susceptibility-weighted Contrast-enhanced Magnetic Resonance Imaging in Glioblastoma for a Longitudinal Assessment of Tumor Perfusion With Cerebral Blood Volume S. Ken, 1 , 2 X. Franceries, 2 T. Filleron, 1 J. Lotterie, 2,3 V. Lubrano, 2,3 L. Vieillevigne, 1 I. Berry, 2,3 P. Celsis, 2 E. Moyal Cohen-Jonathan, 1 and A. Laprie 1,2 ; 1 Institut Claudius Regaud, Toulouse, France, 2 INSERM Imagerie Ce´re´brale et Handicaps Neurologiques UMR 825, Toulouse, France, 3 Centre Hospitalier Universitaire Rangueil, Toulouse, France Purpose/Objective(s): To study the variation of cerebral blood volume (CBV) in glioblastoma multiforme (GBM) in a longitudinal follow-up with the modality of first-pass dynamic susceptibility-weighted contrast- enhanced magnetic resonance imaging (DSC-MRI) in order to assess the tumor perfusion after radiation therapy associated with a radiosensitizer. Materials/Methods: Eighteen patients diagnosed with GBM, included in a prospective clinical trial associating farnesyltransferase inhibitor (tipi- farnib) and conformational 60-Gy radiation therapy (RT) underwent anatomic MRI and DSC-MRI at 1.5T with administration of gadolinium- based (Gd) contrast agent for measurement of cerebral blood volume (CBV) at baseline (M0) before RT concomitant with a radiosensitizer, 2 months after treatment (M2) and then at 2-monthly interval until relapse. Volumes of interest (VOIs) were defined according to regions of hyper- intense signal on contrast-enhanced T1-weighted post-gadolinium (T1-Gd) and on T2-weighted (hyper-T2) MR anatomical images. Perfusion of tumor was measured in these VOIs and normalized with CBV of nonir- radiated tissue taken in the cerebellum, avoiding vascular structures and resulting in relative cerebral blood volume (rCBV). Results: Two groups of patients were found significantly different according to their initial rCBV value at M0 (cut-off rCBV Z 1.0, p < 0.045). Variation of rCBVafter treatment was found significantly different when considering these two groups of patients: rCBV increased when initial rCBV<1.0 and rCBV decreased when initial rCBV  1.0. These results were significant inside both T1-Gd and hyper-T2 volumes of interest, respectively p < 0.009 and p < 0.012. Initial rCBV analyzed as quantitative variable tends to be associated with overall survival (OS). Patients with rCBV  1.00 had a lower OS (median of 11.9 months) compared to patients with rCBV<1.00 (median of OS 22.8 months): HR Z 1.33, 95%IC Z [0.99; 1.80], p Z 0.059. The results of the study lacks of power because of the small number of patients. Conclusions: The measurements of rCBV variations show a trend of tumor perfusion adjustment in agreement with our pre-clinical results of re- oxygenation and vascularization normalization on mice model. The value of initial rCBV measured before treatment could be an indicator of overall survival. Author Disclosure: S. Ken: None. X. Franceries: None. T. Filleron: None. J. Lotterie: None. V. Lubrano: None. L. Vieillevigne: None. I. Berry: None. P. Celsis: None. E. Moyal Cohen-Jonathan: None. A. Laprie: None. 2135 Phase I Safety and Pharmacokinetic (PK) Study of Veliparib in Combination With Whole Brain Radiation Therapy (WBRT) in Patients (pts) With Brain Metastases M.P. Mehta, 1 W.J. Curran, 2 D. Wang, 3 F. Wang, 4 L. Kleinberg, 5 A. Brade, 6 N. Mostafa, 7 J. Qian, 7 T. Leahy, 7 and B. Desai 7 ; 1 Northwestern University, Chicago, IL, 2 Winship Cancer Institute of Emory University, Atlanta, GA, 3 Henry Ford Hospital, Detroit, MI, 4 Kansas University Medical CenterKansas City, KS, 5 Johns Hopkins University, Baltimore, MD, 6 Princess Margaret Hospital, Toronto Canada, ON, 7 Abbott Laboratories, Abbott, ParkIL Purpose/Objective(s): Veliparib is an oral PARP-1 and -2 inhibitor that enhances the antitumor activity of DNA damaging agents and increases efficacy of radiation therapy in several preclinical models. Veliparib has been shown to cross the blood brain barrier and achieve CSF level with doses known to inhibit PARP in human clinical studies. This is an ongoing phase 1 dose-escalation study evaluating the safety, PK, and preliminary antitumor activity of veliparib in combination with WBRT in pts with brain metastases (NCT00649207). Materials/Methods: Pts with brain metastases (including lep- tomeningeal) from primary non-CNS metastatic solid tumors (except germ cell cancer), adequate organ function, and RPA Class 2 and Kar- nofsky performance status 70 were treated with WBRT (37.5 Gy in 15 fractions or 30 Gy in 10 fractions) QD and veliparib BID with daily WBRT, in escalating doses of 10-200 mg; the final WBRT fraction was followed by 1 extra day of veliparib. Safety, PK, and tumor response by RECIST were assessed. Results: To date, 61 pts (M/F, 22/39; median age 57 y) have been treated. Baseline KPS was 70, 80, 90, and 100 in 8.2, 31.1, 39.3, and 21.3% pts, respectively; primary tumor types were breast (n Z 20), NSCLC (n Z 22), melanoma (n Z 9), colorectal (n Z 2), and others (n Z 8); 73.8% pts had multiple lesions, and 18.0% had prior brain stereotactic radiosurgery. Volume 84  Number 3S  Supplement 2012 Poster Viewing Abstracts S269